Immunomedics, Inc. Constructs New Humanized Antibody for B-Cell Mediated Cancer and Autoimmune Diseases

Published: Jul 16, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., July 16, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU),a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024.

Help employers find you! Check out all the jobs and post your resume.

Back to news